Get all your news in one place.
100's of premium titles.
One app.
Start reading
AAP
AAP
Health
Derek Rose

CSL paying $312m to license mRNA vax tech

The next-generation mRNA vaccine technology means a much smaller dose is needed to be effective. (James Ross/AAP PHOTOS) (AAP)

CSL says it is paying $US200 million ($A312m) up-front to license next-generation mRNA vaccine technology from a small US company.

CSL said on Wednesday its CSL Seqirus subsidiary, the second-biggest flu vaccine manufacturer globally, has licensed the technology from NASDAQ-listed Arcturus Therapeutics.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.